newsfilter
← Latest News
GlobeNewswire·

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

  • Gannet BioChem and Serina Therapeutics announced a development partnership on June 30, 2026.
  • Gannet BioChem will support the clinical development of SER-252, an investigational therapy for advanced Parkinson's disease.
  • Serina's Investigational New Drug application for SER-252 recently received FDA clearance.
  • The collaboration combines Serina's proprietary POZ Platform technology with Gannet BioChem's process development & manufacturing expertise.
  • Gannet BioChem CEO Nicholas Shackley emphasized the need for experienced partners to support critical growth stages.
  • Serina CEO Steve Ledger noted Gannet's track record in complex polymer-based therapeutics makes them a complementary partner.
  • The agreement expands Gannet BioChem's portfolio of programs supporting clients from early development through commercialization.
  • The announcement follows Gannet BioChem's participation in the 2026 BIO International Convention.
  • Gannet BioChem is a specialty CDMO focused on activated polymers, including PEG reagents, with over 30 years of industry experience.
  • Serina Therapeutics is a clinical-stage company headquartered in Huntsville, Alabama, developing therapies for neurological diseases.